<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585038</url>
  </required_header>
  <id_info>
    <org_study_id>TMC278HIV4002</org_study_id>
    <nct_id>NCT01585038</nct_id>
  </id_info>
  <brief_title>Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Efavirenz With Rilpivirine on Changes in Endothelial Function, Inflammatory Markers, and Oxidative Stress in HIV-uninfected Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Services, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the cardiovascular profiles of efavirenz and
      rilpivirine, which are two drugs used to treat HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label, single-center study comparing the effects of
      efavirenz (EFV) versus rilpivirine (RPV) on endothelial function in a total of 40
      HIV-uninfected healthy volunteers (20 in each arm) at the Indiana University Medical Center.
      Enrolled subjects will have their brachial artery flow-mediated dilation (FMD), a measure of
      endothelial function, and other cardiovascular, inflammatory, and oxidative stress parameters
      measured at baseline and again after 4 weeks of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow-mediated Dilation of the Brachial Artery</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>This is a measure of in vivo endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Change in high sensitivity C-reactive protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Activation Markers</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Change in soluble vascular cell adhesion molecule-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress Markers</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Change in F2-isoprostane levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600mg given nightly without food for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rilpivirine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rilpivirine 25mg given daily with meals for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>600mg orally every evening</description>
    <arm_group_label>Efavirenz</arm_group_label>
    <other_name>Sustiva, Stocrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine</intervention_name>
    <description>25mg orally once daily</description>
    <arm_group_label>Rilpivirine</arm_group_label>
    <other_name>Edurant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Negative ELISA for HIV-1 or HIV-2 at screening

          3. Negative hepatitis B surface antigen at screening

          4. Negative hepatitis C antibody at screening

          5. For women of reproductive potential, a negative urine pregnancy test at screening and
             willingness to use two forms of birth control during the course of the study

          6. For men who are capable of impregnating a female sexual partner, a willingness to use
             condoms with spermicidal gel for all sexual contacts during the course of the study

          7. No documented history of or receipt of medications being used to treat any psychiatric
             disorder, including (but not limited to) depression, dysthymia, mania, bipolar
             disease, schizophrenia, or previous suicidal ideation/attempts

          8. No anticipated changes or additions to other medical therapies during the course of
             the study

          9. No documented history of seizure disorder

        Exclusion Criteria:

          1. Inability to provide written, informed consent

          2. Known allergy/intolerance to rilpivirine, efavirenz, or nitroglycerin

          3. Absolute neutrophil count &lt; 750cell/mL at screening

          4. Hemoglobin &lt; 11g/dL at screening

          5. Platelet count &lt; 100,000/mL at screening

          6. Estimated creatinine clearance (per Cockcroft-Gault equation) &lt; 55 mL/min at screening

          7. Liver transaminases (AST or ALT) &gt; 100 IU/mL or total bilirubin &gt; 1.5mg/dL at
             screening

          8. Serum glucose &gt; 200mg/dL at screening

          9. Serum total cholesterol &gt; 190mg/dL at screening

         10. Breastfeeding at screening or during the course of the study

         11. Hypotension, defined as SBP &lt; 90mmHg at time of each main study visit before brachial
             artery ultrasound measurements

         12. Hypertension, defined as SBP &gt; 160mmHg at time of screening

         13. Receipt of investigational agents within 30 days of each screening visit or
             anticipated use during the trial

         14. Receipt of cytotoxic chemotherapy within 30 days of each screening visit or
             anticipated use during the trial

         15. Receipt of systemic glucocorticoids (&gt; 10mg/day of prednisone or the equivalent),
             inhaled/nasal/topical fluticasone, or anabolic steroids within 30 days of each
             screening visit or anticipated use during the trial

         16. Use of sildenafil (Viagra or Silagra), vardenafil (Levitra), or tadalafil (Cialis),
             within 72 hours (before or after) of brachial artery reactivity testing

         17. Indwelling vascular catheters within any upper body vessel at time of brachial artery
             reactivity testing

         18. Active drug or alcohol use or dependence that, in the opinion of the investigator or
             study personnel, would interfere with adherence to study requirements

         19. Acute therapy for serious infection or other serious medical illnesses (in the
             judgment of the site investigator) requiring systemic treatment and/or hospitalization
             within 14 days prior to each screening and study visit

         20. History of migraine headaches

         21. History of Raynaud's phenomenon

         22. History of cardiac arrythmias

         23. History of hypothyroidism or hyperthyroidism that is untreated (defined as a TSH
             outside the normal range on most recent testing during normal clinical care)

         24. History of carotid bruits

         25. History of any tobacco use (cigarette smoking, cigar smoking, chewing tobacco) or
             nicotine replacement treatments (patch, gum) within 45 days of screening

         26. Drugs/therapies with significant CYP 450 induction or inhibition potential at
             screening

         27. Use of antacids, H2-blockers, or proton pump inhibitors within 30 days of screening or
             anticipated use of these drugs during the trial

         28. Any history of injection or illicit drug use

         29. Presence of fever, defined as an oral or tympanic temperature &gt; 100.3F, at either the
             Entry or Closeout Visits

         30. On the PHQ-9 depression questionnaire at screening, a total score of more than 9 or
             any score over 0 on question 9.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana Clinical and Translational Sciences Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <results_first_submitted>June 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2015</results_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Samir K Gupta, MD, MS</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>endothelium</keyword>
  <keyword>inflammation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Efavirenz</title>
          <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
        </group>
        <group group_id="P2">
          <title>Rilpivirine</title>
          <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Efavirenz</title>
          <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
        </group>
        <group group_id="B2">
          <title>Rilpivirine</title>
          <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.4" lower_limit="20.3" upper_limit="54.5"/>
                    <measurement group_id="B2" value="34.5" lower_limit="20.4" upper_limit="66.3"/>
                    <measurement group_id="B3" value="31.54" lower_limit="20.33" upper_limit="66.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow-mediated Dilation of the Brachial Artery</title>
        <description>This is a measure of in vivo endothelial function</description>
        <time_frame>Change from baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz</title>
            <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
          </group>
          <group group_id="O2">
            <title>Rilpivirine</title>
            <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Dilation of the Brachial Artery</title>
          <description>This is a measure of in vivo endothelial function</description>
          <units>absolute percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.089" spread="3.65"/>
                    <measurement group_id="O2" value="0.63" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Markers</title>
        <description>Change in high sensitivity C-reactive protein levels</description>
        <time_frame>Change from baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz</title>
            <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
          </group>
          <group group_id="O2">
            <title>Rilpivirine</title>
            <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Markers</title>
          <description>Change in high sensitivity C-reactive protein levels</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="2.47"/>
                    <measurement group_id="O2" value="-0.41" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.71</ci_lower_limit>
            <ci_upper_limit>2.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Activation Markers</title>
        <description>Change in soluble vascular cell adhesion molecule-1 levels</description>
        <time_frame>Change from baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz</title>
            <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
          </group>
          <group group_id="O2">
            <title>Rilpivirine</title>
            <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Activation Markers</title>
          <description>Change in soluble vascular cell adhesion molecule-1 levels</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.62" spread="125.20"/>
                    <measurement group_id="O2" value="-20.92" spread="68.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.49</ci_lower_limit>
            <ci_upper_limit>75.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress Markers</title>
        <description>Change in F2-isoprostane levels</description>
        <time_frame>Change from baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz</title>
            <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
          </group>
          <group group_id="O2">
            <title>Rilpivirine</title>
            <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress Markers</title>
          <description>Change in F2-isoprostane levels</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" spread="178.6"/>
                    <measurement group_id="O2" value="-101.4" spread="215.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-194.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-353.7</ci_lower_limit>
            <ci_upper_limit>-34.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Efavirenz</title>
          <description>Efavirenz 600mg given nightly without food for 30 days
Efavirenz: 600mg orally every evening</description>
        </group>
        <group group_id="E2">
          <title>Rilpivirine</title>
          <description>Rilpivirine 25mg given daily with meals for 30 days
Rilpivirine: 25mg orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Abnormalities</sub_title>
                <description>Diarrhea, abdominal pain, nausea, vomiting</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Abnormalities</sub_title>
                <description>Insomnia, Vivid Dreams, Drowsiness, Dizziness, Headache</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic Abnormality</sub_title>
                <description>Rash or pruritis</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir K Gupta, Md, MS</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-274-7926</phone>
      <email>sgupta1@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

